To combat the increasing incidence of obesity, much research has been devoted to devising successful strategies for weight loss, including manipulation of diet and gastric surgery. Obesity itself can be associated with renal dysfunction, and the degree of reversibility of this with weight loss has being studied. However, there are significant limitations and flaws in the methods we have available to measure glomerular filtration rate (GFR) in overweight and obese subjects. Obesity is associated with changes in body composition including lean and fat mass. This has implications for assumptions that underpin creatinine-based measures such as creatinine clearance, estimated GFR and other equations devised for obesity including the Salazar -Corcoran equation. These changes in body composition also affect measures of glomerular filtration such as cystatin C and nuclear medicine isotope scans. This article will review the accuracy of these current measures of renal function in the obese and consider the evidence for adjusting for body surface area or adjusting for lean body mass. Finally, the effect of weight loss itself on serial measurements of renal function in a given individual, independent of a true change in renal function, will be reviewed. Ultimately using the Cockcroft -Gault equation with an adjustment for lean body mass seems to be the best measure for renal function in obesity. No method for measuring renal function in situations of weight loss has been shown to be unequivocally superior.
INTRODUCTION
The increasing incidence of obesity has led to much interest both from scientists and from the general population about strategies to achieve weight loss. 1 Being overweight or obese at baseline is associated with impaired renal function in large longitudinal cohort studies. Obesity is considered a risk factor for chronic kidney disease (CKD). 2, 3 However, there are discrepancies between different methods of measuring glomerular filtration rate (GFR) such as serum creatinine-derived equations and cystatin C in these obese populations. 2 This can be due to the effect of body composition and that of lean and fat mass (FM) and their role in determining serum creatinine and cystatin C.
This article reviews the utility and pitfalls of the different methods of evaluating GFR in obese subjects. Despite the paucity of clinical trials in this area, the potential difficulties of measuring renal function in situations of weight loss will also be considered as the effect of dieting on body composition is very important.
BODY COMPOSITION IN OBESITY AND WEIGHT LOSS
The traditional approach of describing the relationship between weight (W) and height (H) by body mass index (BMI) expressed as W/H 2 has evolved to consider partitioning BMI into FM index (FM/ H 2 ) and fat-free mass (FFM) index (FFM/H 2 ). The FFM index can be considered a measure of lean body mass. As described in a comprehensive review by Dulloo et al., 4 the FM can be further partitioned into protective and hazardous fat, whereas FFM can be divided into skeletal muscle mass and organ mass. There is a curvi -linear relationship between BMI and percent body fat (%FM), so that there is almost a linear relationship between BMI and body fat up to a BMI of 35 kg m À2 , which tails off with increasing weight at a FM of 55% in women and 40% in men allowing for individual variation. The relationship varies in different ethnic groups and in different age groups. 4 -6 Although many people classified as obese (BMI430 kg m À2 ) will have both an increased FMI and FFMI, in given individuals, the proportion may vary so that at one extreme athletes may have an elevated BMI consisting mainly of FFM with little FM, whereas at the other end of the spectrum are elderly patients with sarcopenic obesity with low FFM and high FM. 7 Weight loss after dieting leads to changes in body composition involving both lean and FM, 8 which was mathematically described by Forbes 9 in 1987. However, the changes in FFM with weight loss are more complex than previously believed. Hall 10 has shown that in situations of large weight loss such as bariatric surgery, the amount of FFM lost can be large and has been traditionally underestimated. To further complicate the situation, Chaston et al. 1 have concluded after a systematic review of 55 weight loss trials that the degree of caloric restriction, exercise, rate of weight loss and even the type of bariatric surgery can influence the proportion of FFM lost during weight loss. As creatinine and cystatin C are correlated with skeletal muscle mass and FM, respectively, the use of these markers of renal function in obese populations and in subjects losing weight can be problematic as discussed below.
METHODS OF MEASURING RENAL FUNCTION
Inulin: the ideal filtration marker Glomerular filtration rate is widely accepted as the best measure of renal function, 11 and can be expressed in relative terms after being corrected for body surface area (BSA) (ml min À1 per 1.73 m 2 ) or in absolute terms, that is, ml min À1 . GFR measures the renal clearance of a particular substance from the plasma and is expressed as the volume of plasma that is completely cleared of that substance in 1 min. 12 Hence, the ideal filtration marker whether exogenous or endogenous would appear in the plasma at a constant rate, and be cleared only by glomerular filtration, that is, not be secreted nor reabsorbed across the tubules. There should also be no non-renal elimination of the substance. Inulin, a 5200D polysaccharide has been traditionally considered an ideal filtration marker. However, it is impractical in clinical practice as it is expensive, time consuming to use and does not lend itself easily to automated measurement. 13, 14 Exogenously administered markers Estimated GFR (eGFR) can also be measured by urinary or plasma clearance of exogenously administered markers such as iohexol, 51Cr-ethylenediaminetetraacetic acid (EDTA) and 99mTc-diethylenetriamine and iothalamate. These markers are now considered the 'gold standard' based on the results of many studies, although the relationship with inulin clearance may vary depending on the technique and the degree of renal disease, 15, 16 and they may overestimate inulin clearance by 3.5 -8 ml min
À1
. 13 Unfortunately, despite the many studies that discuss different methods of evaluating GFR in the obese compared with the 'gold standard', there are few clinical trials validating the 'gold standard' itself compared with inulin clearance in the obese. The other problem with using these exogenous markers to measure GFR is that measurement can be time consuming and impractical outside the research setting.
Thus, alternate measurements of GFR using endogenous blood substances such as serum creatinine or urinary creatinine clearance or serum cystatin C have been used. Both creatinine and cystatin C are more practical to measure clinically than exogenous substances, but can be less accurate particularly in certain patient subgroups including the obese. Predictive equations for both serum creatinine and cystatin C, respectively, have been devised to improve their accuracy. 12, 17 A summary of the disadvantages and advantages of the different measures of renal function in obesity are summarized in Table 1 .
CREATININE-BASED METHODS

Serum creatinine
Creatinine is a 113D amino acid that is freely filtered at the glomerulus and the generation of which is primarily determined by muscle mass and dietary protein. 14 As it is freely filtered at the glomerulus with some secretion by cells of the proximal tubule, creatinine clearance will exceed GFR. Serum creatinine itself has been shown repeatedly to be inversely related to GFR and is widely used as an estimate of renal function. 12 It is convenient to perform. However, as serum creatinine is proportional to FFM, specifically the lean muscle component, its use to measure renal function is compromised in situations of low muscle mass, for example, in the elderly, malnourished and in females. GFR will be overestimated in sarcopenic obesity in which there is considerable loss of lean body mass in the presence of increased FM. 7 In more typical obese subjects in whom lean and FM can both be increased, serum creatinine will be increased and imply renal function is worse than it is.
Creatinine clearance Measured creatinine clearance requires 24-h urine collections. It is cumbersome and overestimates GFR by up to 19% compared with eGFR. 18 In healthy obese subjects, although both FM and FFM are increased compared with lean individuals of the same height, the creatinine clearance is increased in proportion to FFM and hence is even more inaccurate. Sometimes in the obese, creatinine clearance is indexed to BSA. This topic will be discussed below. 19 The formula for calculating creatinine clearance is shown below.
Cr clearance ðml min À1 Þ ¼ urinary creatinine conc Â24 h volume=ðplasma creatinine conc Ã 1440Þ
Cockcroft -Gault formula The Cockcroft -Gault Formula was a creatinine-based equation first derived in 1976. It takes into account age, weight and gender to estimate creatinine clearance. 20 The formula is Cr clearanceðml min À1 Þ ¼ fð140 À ageÞÂwtðkgÞÂFg =ðplasma creatinine Ã 0:8136Þ where F ¼ 1 if male and F ¼ 0.85 if female and creatinine is in mmol l
À1
. The Cockcroft -Gault formula has been widely validated against various 'gold standards' including inulin, 51Cr-EDTA and DTPA (diethylene triaminopentaacetic acid). 13 Its incorporation of age and female sex recognizes that the lower lean muscle mass in these groups do not reflect a higher GFR. However, the adjustment for weight is insufficient in the obese in whom the extra weight occurs disproportionately as fat and so overestimates GFR. 21 The two approaches have been to adjust for BSA or lean body weight (LBW).
Cockcroft -Gault formula adjusted for BSA There has been a tradition to express GFR as ml min À1 per 1.73 m 2 . The '1.73 m 2 ' represented the average adult BSA in 1916, although clearly this is no longer the case. 22 Since then, GFR measurements whether gold-standard radioisotope nuclear scans or 24-h creatinine clearance measurements are expressed in ml min However, Levey and Kramer 24 argue that the actual rationale for adjusting for BSA in the obese is not entirely clear. The accepted dogma is that GFR and renal plasma flow are proportional to kidney size, which is proportional to body weight. A heavier subject would be expected to have higher metabolic demands and produce more wastes, which need clearance by the kidneys and thus be responsible for higher GFR. However, increased GFR arises not by an increased nephron number which is fixed at birth but also by hyperfiltration. As it is still unclear whether this is physiological or pathological, correcting for BSA may be normalizing a disease state. Moreover even if adjusting for BSA was correct, the formulae used such as the Du Bois formula have not been conclusively validated in the obese. 24 Cockcroft -Gault formula adjusted for LBW Some researchers including Gault himself have suggested using LBW (that is, FFM) in the formula rather than actual body weight. 25 Although not universally accepted, there is some evidence for this. Ozmen et al. 26 have shown in 110 Caucasian subjects of varying weight that the Cockcroft -Gault formula overestimates GFR per ml min À1 per 1.73 m 2 in obese but not in healthy subjects with CKD. However, they showed that using lean body mass, measured by leg-to-leg bio-impedance, improved GFR estimation in the obese subgroup. Lim et al. 27 have also shown that in 56 subjects with normal renal function that the Cockcroft -Gault equation adjusted for lean body mass and BSA conformed best with measured renal function by technetium Tc 99m-labeled DTPA.
MDRD formula
Background. Many laboratories now quote an eGFR on routine laboratory reports of renal function using mathematical formulae. Although there are at least 46 prediction equations available, besides the Cockcroft -Gault equation mentioned above, the abbreviated MDRD formula is widely used. 13 The MDRD formula was first devised by Levey et al.
18 using cross-sectional data obtained from the MDRD study. The goldstandard measure of GFR was iothalamate clearance. Subsequently with the advent of the new gold-standard isotope dilution mass spectrometry-traceable serum creatinine assays, Levey studied 29 obese subjects with a BMI of 45 ± 10 kg m À2 and serum creatinine of 62 ± 18 mmol l À1 . The agreement between an iohexol clearance and creatinine-based equations including the MDRD formula was fair to poor in this study. Bird et al. 30 showed that eGFR compared poorly with both CR 51-EDTA and iohexol GFR in subjects generally but particularly those with BMI429 kg m
À2
.
MDRD vs Cockcroft -Gault.
There is conflicting evidence about whether the MDRD formula is superior to the Cockcroft -Gault equation in the obese. A French study examined 2095 men and women with median measured GFR of 59.8 ml min À1 per 1.73 m 2 . The gold standard was renal clearance of 51-Cr-EDTA and GFR was estimated by both Cockcroft -Gault using total weight and adjusting for BSA and the MDRD formula. 31 In the 279 subjects with a BMI430 kg m À2 , the Cockcroft -Gault equation overestimated measured GFR by B9.0 ml min À1 per 1.73 m 2 compared with the MDRD, which underestimated measured GFR by B2.5 ml min À1 per 1.73 m 2 . Conversely, the MDRD formula performed badly in a study of 850 men and women with normal renal function, compared with the gold standard of continuously infused (99m) Tc DTPA. 32 In the obese group with BMI430 kg m À2 , the gold-standard GFR was 99.0 ± 21.6 ml min À1 per 1.73 m 2 . The MDRD yielded a GFR of 87.4 ± 16.0 and 70.9 ± 11.7 ml min À1 per 1.73 m 2 when serum creatinine was measured using enzymatic and Jaffe methods, respectively. The Cockcroft -Gault equation, using total body weight adjusted for BSA, also performed badly in this study and was not recommended (data not shown).
In a study of 293 predominantly male Caucasian diabetic subjects, both Cockcroft -Gault and MDRD generally underestimated GFR measured by isotope scan but the MDRD was less accurate with increasing body weight compared with the Cockcroft -Gault, which also became less inaccurate with increasing weight. 33 One reason for the discrepancy may have been that subjects were newly diagnosed diabetics and that all tertiles of body weight had mean measured GFR 4110 ml min À1 per 1.73 m 2 . The accuracy of MDRD is not well validated at normal or high GFRs such as was typical for this subgroup. 34 Although there is conflicting data about whether the MDRD is superior to the Cockcroft -Gault (adjusted for BSA) in the obese, the incorporation of lean body mass into the Cockcroft-Gault seems to yield better results than the MDRD. In the study by Ozmen et al. 26 above, the formula incorporating lean body mass performed better than the four-variable MDRD equation. In the study by Demirovic et al. 35 of 54 morbidly obese subjects with normal renal function mentioned above, using a measure of LBW incorporated into the Cockcroft -Gault equation outperformed the MDRD equation.
In 2005, the International Society of Nephrology came up with a position statement to streamline the definition and classification of CKD and considered the issue of measurement of eGFR among other issues. 34 They noted that the MDRD was less well validated in the obese (BMI435 kg m À2 ), as well as in those with normal renal function and conditions associated with hyperfiltration both of which can be present in the obese. In addition, the large differences between GFR adjusted and unadjusted for BSA were noted in the obese. Others have also noted that as the MDRD is indexed to a normalized BSA of ml min À1 per 1.73 m 2 , conversion to nonnormalized BSA will overestimate GFR in obese subjects. 36 Having said this, some studies quoted above show that the CockcroftGault equation underestimates GFR compared with isotope scans. 33 Salazar and Corcoran equations What about eGFR prediction equations that have been developed for the obese? Salazar and Corcoran 19 first published their seminal paper in 1988. On the basis of studies in obese overfed rats, they showed that creatinine clearance was directly proportional to FFM. Using published formulae for FFM and previously published data from Kampmann et al. 37 of 149 males and 219 females, wherein details of weight, BSA and 24-h creatinine clearance were available, they derived two equations for creatinine clearance. On the basis of calculations in 12 obese and 9 normal-weight subjects, they claimed that their equations were as accurate as existing methods for normal-weight subjects and far superior to existing methods for obese subjects. 37 The Salazar -Corcoran equation is shown below where height is in meters, weight in kilograms and serum creatinine in mg dl CCr ðfemalesÞ ¼ ½146 À ageÂ½ð0:287ÂweightÞ
Several studies have confirmed the utility of the Salazar -Corcoran equation in other cohorts such as obese renal transplant patients and 208 obese patients awaiting cardiac angiography wherein equations that do not incorporate weight such as the Jellife equation are found wanting. 38, 39 The Salazar -Corcoran equation is now often used as a gold standard against which other equations are compared in obese subjects. 40 However, the Salazar -Corcoran equation has been criticized for not being sufficiently validated in obese populations. 13 In studies such as that by Demirovic et al. quoted above, the modified CockcroftGault equation using LBW proved superior to the SalazarCorcoran equation in morbidly obese subjects.
Other equations to calculate creatinine clearance in obese subjects such as suggested by Saracino et al. 41 have not been as widely used by others.
Therefore, of the creatinine-based methods, the best-validated method to currently evaluate renal function in the obese is to use the Cockcroft -Gault equation using lean body mass and then the Salazar -Corcoran equation.
CYSTATIN C Cystatin C is a 13.4-kDa non-glycosylated basic protein and a member of the cystatin superfamily of cysteine protease inhibitors. 12 It is continually produced by nucleated cells and is removed from the circulation by glomerular filtration and then metabolized by epithelial cells in the proximal tubules after resorption. In the absence of significant tubular damage, cystatin C is reabsorbed and metabolized by proximal tubular epithelial cells making it a reliable marker of GFR. 42 Hence, higher cystatin C concentrations are associated with renal dysfunction and eGFR can be estimated from the inverse of cystatin C concentrations or by using equations. 43 These equations can use cystatin C alone, or use age, sex and race or even incorporate serum creatinine. An example is shown below the cystatin-based equations taken from a pooled analysis of 3418 subjects with chronic renal impairment from Stevens et al. 44 using urinary clearance of 125I-iothalamate or 51-Cr-EDTA as the gold standard. In this study, it must be noted that the equation combining cystatin C with creatinine and age, sex and race performed the most favorably. 45 but not gender. 46, 47 However, this review will limit comparison of Cystatin C with other methods in the obese group.
An important cross-sectional study was performed by Knight et al. 48 on 8058 subjects aged 28 -75 years from the Netherlands comparing cystatin C and 24-h creatinine clearance. Even after adjusting for creatinine clearance, they found that greater weight and greater height among other factors such as greater age and male gender were independently associated with higher serum cystatin C levels.
In a study using 6709 participants from the adult Third National Health and Nutrition Examination Survey, the incidence of stage 3 or 4 CKD was determined by creatinine-and cystatin C-based equations. 49 The prevalence of stage 3 or 4 kidney disease was always higher across all BMI groups using cystatin C equations (except for combined cystatin C, creatinine equation) compared with eGFR using MDRD. There was a greater discrepancy in the overweight (BMI 25.0 -29.9 kg m
À2
) and even more in the obese subjects (BMIX30.0 kg m À2 ). As no gold-standard measure of renal function was used in this study, it was not possible to determine whether cystatin C overestimated renal disease or the MDRD underestimated it or both.
Schuck et al. 50 sought to compare the utility of cystatin C in 33 obese patients with chronic renal disease (S cr ¼ 227 ± 118 mmol l . Receiver operating characteristic curve analysis (using a cutoff value for Cin ¼ 30 ml min À1 per 1.73 m 2 ) did not show significant differences in area under curve, sensitivity and specificity for serum cystatin between obese and non-obese patients. They concluded that the GFR based on serum cystatin in obese patients need not differ from that in non-obese ones and were quite accurate as well.
An attempt was made to tease out the association between cystatin C, renal function and visceral adipose tissue and subcutaneous adipose tissue by a computerized axial tomography scan in a subset of 1299 participants from the Framingham Offspring Study. 51 In this cohort with a mean age of 60±9 years, the prevalence of CKD (GFRo60 ml min À1 per 1.73 m 2 ) was 6.8% using MDRD GFR and 10.5% using cystatin C-based GFR. There was no association between visceral adipose tissue and subcutaneous adipose tissue and CKD as defined by MDRD as there was for cystatin-based equations. The decrease in eGFR by cystatin C per 1 s.d. increase of visceral adipose tissue was 1.9 ml min À1 per 1.73 m 2 and that for subcutaneous adipose tissue was 2.6 ml min À1 per 1.73 m 2 in a multivariable-adjusted model. The authors suggest two non-mutually exclusive explanations. First in this older cohort, creatinine-based markers of eGFR may underestimate renal dysfunction due to loss of muscle mass compared with cystatin C, which is not reliant on muscle mass. Second, the increased adipose tissue may be responsible for some of the increased cystatin C production perhaps medicated by adipokines and cytokines including leptin, resistin and adiponectin. Naour et al. have shown that cystatin C gene expression and release by adipose tissue explants are increased twofold to threefold in obesity. They have also suggested that elevated cystatin C is independent of GFR. 52 There is evidence for this. In the Cardiovascular Health Study, 4295 subjects were followed for up to 7 years with one of the aims being to determine the effect of baseline weight on deterioration in renal function as assessed by MDRD GFR and cystatin C.
2 There were 43% of subjects who were overweight and 19% who were obese. Although baseline obesity predicted longitudinal loss of GFR using the MDRD GFR, this association did not hold for GFR estimated by cystatin C. One possibility suggested was that for subjects who were more obese at baseline, loss of renal cystatin C clearance was balanced by loss of simultaneous cystatin C production, which partly derives from adipocytes. The authors argue that this hypothesis is supported by the inverse relationship between obesity and GFR measured by cystatin C at baseline. As creatinine is produced by muscle not fat, equations derived from serum creatinine are not affected by changes in FM. This study would suggest that FM decreased over time, which is not necessarily what might have been expected.
If cystatin C does increase with increased adiposity independent of renal function, then this could explain why the incidence of kidney disease is higher using cystatin C-based methods compared with creatinine-based methods as discussed above.
What about the relationship between cystatin C and muscle mass? Traditionally, cystatin C was considered independent from FFM including body cell mass (FFM without bone mineral mass and extracellular water). 53 However, there was a contrary study by Macdonald et al. 54 who studied 77 subjects with chronic renal impairment. GFR determined by inulin clearance was the gold standard. Equations that included just cystatin C underperformed than did equations using cystatin C and lean mass in being able to predict GFR in patients with extreme body mass (LM (lean mass) or FM4 ± 1 s.d.). However, other studies have also not found an association between cystatin C and body composition that is, either lean or FM. Just as obesity can be associated with different manifestations of renal dysfunction such as proteinuria, hyperfiltration and reduced GFR, weight loss can induce improvement in these measures. For example, Currie et al. 55 recently reviewed the effect of bariatric surgery on renal function and cited studies showing improvements in serum creatinine, hyperfiltration and proteinuria. However, it is difficult to find studies that consider the effect of weight loss itself on the accuracy of their tests of renal function when body composition is changed.
Weight loss and body composition Although there are no prospective clinical trials in this area, one might infer that with such physiological changes after weight loss, comparison of renal function before and after weight loss in the same individual should be approached cautiously. Not only is there the loss of creatinine-producing muscle cells from lean tissue, the alterations in fluid regulation might alter the steady-state clearance of creatinine. A similar argument could be used for cystatin C, which is produced from adipocytes as discussed above. 52 
WEIGHT LOSS AND MEASURES OF RENAL FUNCTION
As an example, Saliba et al. 56 studied 35 diabetic and non-diabetic subjects who lost between 33 (diabetic) and 35% (non-diabetic) of baseline weight after Roux-en-Y gastric bypass. Measured creatinine clearance decreased 15% in diabetics (P ¼ 0.02) and 21% in nondiabetics (P ¼ 0.03) after 12 months, which suggested a reduction in hyperfiltration. The effect of weight loss on muscle mass loss and creatinine generation can only be inferred and may have potentially skewed the results even if there was a true improvement in renal function. This study also measured change in urine cystatin C-to-creatinine ratio. This is a marker of renal tubular injury as cystatin C is largely resorbed and metabolized in the tubules in subjects with preserved tubular function. This study actually suggested a worsening in the ratio and hence tubular function after gastric bypass in diabetics. However, if there was a loss of FM and cystatin C generation, then the measured urinary cystatin C after surgery compared with before surgery might underestimate the increased tubular damage. Similarly, a retrospective study of 140 morbidly obese subjects after Roux-en-Y gastric bypass showed a reduction in creatinine clearance and hyperfiltration. 57 Interestingly, in another study that showed improvement in hyperfiltration and proteinuria after bariatric surgery, the authors specifically did not measure renal function by MDRD or Cockcroft -Gault equation because of the problems with these methods in obesity as mentioned earlier. 58 However, measured creatinine clearance was uncorrected for BSA, so as not to underestimate GFR.
The effects of lean muscle mass loss after gastric surgery should not be underestimated. Tamboli et al. 59 have shown that LM loss constituted 27.8 ± 10.2% of total weight loss achieved at 12 months. Neither change in serum creatinine nor eGFR was reported for this study, but even if this was measured, the change in lean muscle mass would have skewed the result and potentially overestimated any change in creatinine. This should not be interpreted that renal function does not improve at all with weight loss, but that our methods to measure renal function in weight loss are imperfect. Chagnac et al. 60 have shown that in 8 subjects undergoing gastroplasty whose BMI decreased by 16 Units, from 48±2.4 to 32.1±1.5 (Po0.0001), there were objective improvements in renal function. After weight loss, albumin excretion rate decreased from 16 (4-152 mg min À1 ) to 5 mg min À1 (3-37 mg min À1 ) (Po0.01), whilst there was resolution of hyperfiltration with GFR measured by inulin clearance dropping from 145±14 to 110 ± 7 ml min À1 (P ¼ 0.01). Unfortunately, the concomitant changes in creatinine were not reported. It would have been interesting to correlate the change in GFR measured by creatinine-based methods with change in GFR measured by inulin clearance. 60 In a retrospective analysis of 757 patients who underwent gastric surgery, who had baseline serum creatinine measurements at baseline and after 24 months from bariatric surgery, renal function as measured by serum creatinine was stable or improved.
However, although the acute effect of surgery would have resolved, no allowance is made for the loss of lean mass which may have affected creatinine. 61 Hence, in many studies of weight loss, in which renal function is an outcome measure, the effect of changes in body composition on endogenous markers such as creatinine and cystatin C may not have been sufficiently considered.
CONCLUSIONS
Choosing the best method to accurately estimate GFR in the obese is not straightforward because of conflicting studies and comparisons with gold-standard clearance of exogenous markers, which have not themselves been as well validated in this population. In terms of creatinine-based methods, the Cockcroft -Gault equation using lean body mass rather than adjusted for BSA would appear to be a superior test to serum creatinine or 24-h urine collections to determine creatinine clearance. The MDRD equation is not sufficiently validated in obese populations; hence, its role in obese populations with impaired renal function awaits further prospective studies. Similarly, the utility of the Salazar -Corcoran equation, although potentially promising in the overweight and obese population, needs to be more widely validated.
Although cystatin C may outperform creatinine-based methods in some clinical situations, it cannot be recommended as being a superior method of measuring GFR in obesity because of the fact that it may be produced by adipocytes and in the absence of more clinical trials.
Finally, in situations of dieting and weight loss in which the body composition changes and there are alterations in body water and lean and FM, all current methods of estimating GFR are potentially flawed. These limitations in our measures of estimating GFR restrict our ability to quantify the effect of weight loss in improving renal function in the obese.
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